• 15 May 2019
    X4 Pharmaceuticals and The Leukemia & Lymphoma Society Announce Collaboration to Advance Development of Mavorixafor in Waldenström’s Macroglobulinemia

    X4 Pharmaceuticals, Inc. (Nasdaq:XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, and The Leukemia & Lymphoma Society (LLS) today announced a collaboration to accelerate the development of X4’s lead product candidate, mavorixafor (X4P-001) for the treatment of Waldenström’s macroglobulinemia (WM), a rare form of non-Hodgkin lymphoma.

    Mavorixafor was selected for LLS’s Therapy Acceleration Program® (TAP), a strategic initiative where LLS builds business alliances and collaborations with biotechnology companies and academic researchers to speed the development of new therapies for blood cancers. Under the collaboration, X4 will conduct a multi-national Phase 1/2 clinical trial to evaluate the safety and assess the preliminary anti-tumor activity of mavorixafor in combination with ibrutinib in WM patients. The trial is planned to commence this year. Lee Greenberger, Ph.D., chief scientific officer of LLS, will also serve as a member of an advisory board to X4, providing important strategy and partnership guidance throughout the trial.

    “LLS’s selection of mavorixafor for TAP collaboration and investment reinforces its potential as a novel therapy for Waldenström’s macroglobulinemia. Approximately 30 to 40 percent of WM patients have a CXCR4 mutation, and a number of these patients do not respond well to current therapies,” said Paula Ragan, Ph.D., president and chief executive officer of X4 Pharmaceuticals. “We look forward to working closely with Dr. Greenberger and the LLS TAP team to gain valuable data and insights throughout the upcoming clinical trial as we work to bring a new therapeutic option to patients with this rare form of cancer.”

    Mavorixafor is a first-in-class, oral, small molecule allosteric antagonist of the chemokine receptor CXCR4 and is designed to address certain rare primary immunodeficiency diseases and certain cancers, including lymphomas, in which genetic mutations in CXCR4 create abnormal trafficking of white blood cells and play a role in disease process.

    “Through TAP, LLS is committed to advancing the development of promising investigational therapies that we believe have potential to improve standards of care for patients, especially in disease areas with high unmet medical need, such as Waldenström’s macroglobulinemia,” said Dr. Greenberger. “Mavorixafor has demonstrated early promise in other disease areas with CXCR4 mutations, including solid tumors, and its potential application among CXCR4-mutant WM patients makes it an excellent fit and an important asset within our program as we work with innovative companies like X4 to uncover and develop cutting-edge therapies for patients with blood cancers.”

    About Waldenström’s Macroglobulinemia
    Waldenström’s macroglobulinemia (WM) is a rare form of non-Hodgkin lymphoma and B-cell lymphoproliferative disorder. According to the American Cancer Society, approximately three per one million people are diagnosed each year, including 1,400 new cases in the United States annually. Recent advancements in whole-genome sequencing have identified genetic mutations in the disease similar to WHIM syndrome, a rare congenital primary immunodeficiency characterized by warts, hypogammaglobulinemia, infection and myelokathexis. Approximately 30 to 40 percent of WM cases express mutations in the CXCR4 gene in the cancer cells. In WM, somatic mutations of CXCR4 are associated with active tumor cells and possible drug resistance, including resistance to anti-CD20 monoclonal antibodies and Burton tyrosine kinase (BTK) inhibitors, such as ibrutinib, the current standard of care. WM patients with this somatic mutation have a dramatically reduced median progression-free survival, or mPFS, of approximately two years, whereas patients without the mutation have a mPFS of well over five years.

    About the Therapy Acceleration Program®
    The Leukemia & Lymphoma Society’s Therapy Acceleration Program® (TAP) identifies and funds innovative projects related to therapies, supportive care or diagnostics that have the potential to change the standard of care for patients with blood cancer, especially in areas of high unmet medical need. TAP funding assists both clinical investigators and companies in gaining critical clinical proof of concept data that better enables them to obtain the resources they need or a partner to complete the testing, registration and marketing of new treatments, supportive care and diagnostics for leukemia, lymphoma and myeloma. TAP funding is different from the traditional grant at LLS. The TAP review process is separate from the grant process and LLS’s TAP staff play an active advisory role and closely monitor each approved project. To learn more about how TAP works, please click here.